LY3478045 + atorvastatin

LY3478045 + atorvastatin is a combination of two drugs: LY3478045, a small molecule inhibitor of ketohexokinase (KHK), and atorvastatin, a widely used statin that inhibits HMG-CoA reductase. LY3478045 is under investigation primarily as a metabolic modulator targeting disorders like diabetes, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis by inhibiting fructose metabolism via KHK[4]. Atorvastatin is an established lipid-lowering agent used to reduce cholesterol and cardiovascular risk by inhibiting HMG-CoA reductase. As of September 2025, there is no evidence that this exact combination (LY3478045 + atorvastatin) is marketed or has a unique brand or code name; rather, this would refer to the co-administration of these two drugs (possibly in a clinical study or experimental context).